RAPT Therapeutics (RAPT, Financial) has appointed Dr. Jessica Savage as Vice President of Clinical Development to lead the development efforts for their innovative monoclonal antibody, RPT904. This antibody is engineered to bind with free human immunoglobin E, which plays a critical role in various allergic diseases.
The company aims to initially focus the development of RPT904 on treating food allergies and chronic spontaneous urticaria. Dr. Savage brings extensive experience to her new role, having previously worked as the Senior Medical Director at Alexion, part of AstraZeneca’s Rare Disease Unit. There, she spearheaded the clinical development strategy for ALXN2050, targeting Lupus Nephritis and IgA Nephropathy, overseeing crucial Phase 2 clinical trials and making preparations for Phase 3.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for RAPT Therapeutics Inc (RAPT, Financial) is $5.00 with a high estimate of $10.00 and a low estimate of $2.00. The average target implies an upside of 439.96% from the current price of $0.93. More detailed estimate data can be found on the RAPT Therapeutics Inc (RAPT) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, RAPT Therapeutics Inc's (RAPT, Financial) average brokerage recommendation is currently 2.8, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
